APRI (Apri), Drug Delivery System, Patient Friendly Drugs San Diego by Apricus Bio

Apricus Bio APRI NexACT

HOME

ABOUT APRICUS

PRODUCTS

DEVELOPMENT PIPELINE

INVESTOR RELATIONS

Investor Relations

Press Releases

Media & Events Press Releases Stock Quotation Fact Sheet SEC Filings SEC Filings - XBRL Content Corporate Governance Corporate Presentation Social Media Videos		Press Releases Press Releases \| Archives
		2012 14May May, Monday 14, 2012¬ 09:43 EDT Apricus Biosciences to Present at the 11th Annual JMP Securities Research Conference 11May May, Friday 11, 2012¬ 09:56 EDT Health Canada Grants Apricus Biosciences Pre-NDS Meeting for MycoVa™ for the Treatment of Onychomycosis 08May May, Tuesday 08, 2012¬ 09:50 EDT Apricus Biosciences Announces First Quarter 2012 Financial Results Conference Call and Provides Corporate Update 07May May, Monday 07, 2012¬ 10:11 EDT Health Canada Grants Apricus Biosciences Pre-NDS Meeting for Femprox for Female Sexual Arousal Disorder 04May May, Friday 04, 2012¬ 10:06 EDT Apricus Biosciences Announces Poster Presentation of Femprox^® Phase III Clinical Data at American Urological Association Annual Meeting 27apr April, Friday 27, 2012¬ 10:37 EDT Apricus Biosciences Shareholder Notice: Vice President Edward Cox Interviewed on OneMedPlace 26apr April, Thursday 26, 2012¬ 12:02 EDT Apricus Biosciences Receives Notice of Issuance for First Prevonco™ Patent in the United States 22Mar March, Thursday 22, 2012¬ 07:01 EDT Apricus Biosciences Announces Allowance of a NexACT^® Technology-Based Patent in Europe for the Manufacture of DDAIP 14Mar March, Wednesday 14, 2012¬ 10:06 EDT Apricus Biosciences, San Diego Hospice And The Institute For Palliative Medicine Announce A Broad Clinical Research Program Using Nexact^® Technology 09Mar March,Friday 09, 2012¬ 08:01 EDT Apricus Biosciences' CEO to Present at the 24th Annual ROTH OC Growth Stock Conference 08Mar March, Thursday 08, 2012¬ 14:22 EDT Apricus Biosciences Announces 2011 Year End Financial Results Conference Call 08Mar March, Thursday 08, 2012¬ 10:04 EDT Apricus Biosciences, Inc [APRI] to Ring The NASDAQ Stock Market Closing Bell 06Mar March, Tuesday 06, 2012¬ 10:01 EDT APRICUS BIOSCIENCES CEO IS INTERVIEWED ON CDTV.NET 16Feb February, Thursday 16, 2012¬ 10:08 EDT Apricus Biosciences Announces Shareholder Update With New Focus as a Commercially-Driven Specialty Pharmaceutical Company 15Feb February, Wednesday 15, 2012¬ 12:37 EDT Apricus Bioscience's Wholly-Owned Subsidiary NexMed (USA) Signs Exclusive German Collaboration for Vitaros^® for Erectile Dysfunction 09Feb February, Thursday 09, 2012¬ 09:30 EDT Apricus Biosciences Prices $20.0 Million Public Offering Of Common Stock And Warrants 08Feb February, Wednesday 08, 2012¬ 17:22 EDT Apricus Biosciences Announces Proposed Public Offering Of Common Stock And Warrants 03Feb February, Friday 03, 2012¬ 11:27 EDT Apricus Biosciences Announces Acquisition Of Nitromist™ Rights Outside North America 27Jan January, Friday 27, 2012¬ 08:02 EDT Apricus Biosciences Expands Commercial Oncology Offerings Through Agreement With Pediatrx for U.S. Co-Promotion of GRANISOL^® (Granisetron) Oral Solution ... 19Jan January, Tursday 19, 2012¬ 11:02 EDT Apricus Biosciences Retains Argot Partners As Investor Relations Firm 17Jan January, Tuesday 17, 2012¬ 10:08 EDT Apricus Biosciences Announces Allowance of Israeli Patent, Expanding Its Patent Portfolio for the Topical Treatment of Premature Ejaculation 10Jan January, Tuesday 10, 2012¬ 10:56 EDT Apricus Biosciences and Elis Pharma Sign License Agreement for MycoVa™ in the Middle East and the Gulf 09Jan January, Monday 09, 2012¬ 16:16 EDT Apricus Biosciences To Webcast Today’S Presentation At Biotech Showcase™ 2012 In San Francisco 09Jan January, Monday 09, 2012¬ 12:34 EDT Apricus Biosciences and Abbott Sign Exclusive Agreement to Market Vitaros^® (Alprostadil) in Canada 04Jan January, Wednesday 04, 2012¬ 09:55 EDT Apricus Biosciences CEO, Dr. Bassam Damaj, to Present at Biotech Showcase™ 2012 in San Francisco 03Jan January, Tuesday 03, 2012¬ 10:05 EDT Apricus Biosciences and Stellar Pharmaceuticals Announce Exclusive License Agreement in Canada for the Commercialization of MycoVa™ for Onychomycosis 2011 29Dec December, Thursday 29, 2011¬ 12:35 EDT Apricus Biosciences Completes Acquisition of Topotarget USA, Inc. 16Dec December, Friday 16, 2011¬ 08:06 EDT Apricus Biosciences Launches Commercialization Arm With Definitive Agreement to Acquire Topotarget USA 15Dec December, Thursday 15, 2011¬ 10:05 EDT Apricus Biosciences Announces Oral Presentation of Efficacy and Clinical Safety Data for Vitaros^® and Femprox^® at the African Society for Sexual Medicine Conference 12Dec December, Monday 12, 2011¬ 11:58 EDT Apricus Biosciences' Vitaros^® Podium Presentation Named Best Clinical Presentation 2011 (Male Sexual Disorder) by the Scientific Committee of the Congress ... 08Dec December, Thursday 08, 2011¬ 10:06 EDT Apricus Biosciences Announces Allowance of Additional NexACT^® Patent in Japan 30Nov November, Wednesday 30, 2011¬ 09:48 EDT Apricus Biosciences Announces Podium Presentation of Efficacy and Clinical Safety Data for Vitaros^® at the European Sexual Society Medicine Conference 21Nov November, Monday 21, 2011¬ 09:56 EDT Apricus Biosciences Announces Appointment of Dr. Kleanthis G. Xanthopoulos to Its Board of Directors 15Nov November, Tuesday 15, 2011¬ 09:36 EDT Apricus Biosciences Announces That Its NexACT^® Partner Exodos Life Sciences Has Completed Its pre-IND Meeting With the FDA 14Nov November, Monday 14, 2011¬ 09:52 EDT Femprox^® Phase III Clinical Data From Apricus Biosciences Chosen for a Presentation at the European Society for Sexual Medicine 11Nov November, Friday 11, 2011¬ 13:21 EDT Apricus Biosciences Announces Third Quarter 2011 Financial Results Conference Call 19Oct October, Wednesday 19, 2011¬ 10:36 EDT Apricus Biosciences Announces Issuance of Korean Patent, Expanding Its Patent Portfolio for Its Topical Cream to Treat Premature Ejaculation 13Oct October, Thursday 13, 2011¬ 11:21 EDT Apricus Biosciences Announces New Data Published in the International Journal of Pharmaceutics Confirming Efficiency of NexACT^® Drug Delivery Technology 10Oct October, Monday 10, 2011¬ 10:36 EDT Apricus Biosciences Announces Presentation of Efficacy and Clinical Safety Data for Vitaros^® at Upcoming Industry Conference 06Oct October, Thursday 06, 2011¬ 10:57 EDT Apricus Biosciences to Present Poster of Femprox^® Phase III Clinical Data at Upcoming Industry Conference 04Oct October, Tuesday 04, 2011¬ 10:06 EDT Apricus Biosciences to Present NexACT^® Technology Overview at PODD Drug Delivery Conference 03Oct October, Monday 03, 2011¬ 11:08 EDT Apricus Biosciences Announces Korean Patent Approval for MycoVa™ for Nail Fungus 09Sep September, Friday 09 2011¬ 14:28 EDT Apricus Biosciences to Provide Overview of Rx and Consumer Healthcare Divisions at the 11^th Annual Biotech in Europe Investor Forum 02Sep September, Friday 02 2011¬ 10:38 EDT Apricus Biosciences Corrects the Terminology Relating to Its OTC Products 15Aug August, Thursday 15 2011¬ 10:08 EDT Apricus Biosciences Announces Expansion of Its NexACT^® Patent Portfolio 11Aug August, Thursday 11 2011¬ 16:35 EDT Apricus Biosciences Announces Second Quarter 2011 Financial Results Conference Call 11Aug August, Thursday 11 2011¬ 11:39 EDT Apricus Biosciences CEO Interviewed on CEOLIVE.TV 08Aug August, Monday 08 2011¬ 10:08 EDT Apricus Biosciences To File For Market Authorization To Sell Vitaros^® For Erectile Dysfunction In Latin America 04Aug August, Thursday 04 2011¬ 13:27 EDT Apricus Biosciences Provides Corporate Mid-Year Update 19Jul July, Tuesday 19 2011¬ 09:59 EDT Apricus Biosciences Files Marketing Application for Vitaros^® as a Treatment for Erectile Dysfunction in Switzerland 06Jul July, Wednesday 06 2011¬ 09:05 EDT Apricus Biosciences Sells Bio-Quant CRO Subsidiary to BioTox Sciences 28Jun June, Tuesday 28 2011¬ 10:52 EDT Apricus Biosciences' Marketing Application for Vitaros^®, for the Treatment of Erectile Dysfunction, is Accepted for Review in Europe 27Jun June, Monday 27 2011¬ 10:19 EDT Apricus Biosciences Reports Reanalysis of Its U.S. Phase III Trials for MycoVa™ Showing Drug is Effective in Mycological Cure Resulting in Eradication of Nail Fungus 24Jun June, Friday 24 2011¬ 10:40 EDT Apricus Bio CEO Bassam Damaj to Present at the 2011 Biotechnology Industry Organization (BIO) International Convention 17Jun June, Friday 17 2011¬ 14:28 EDT Apricus Biosciences' CEO Sees Higher Revenue if Pfizer Viagra^® Litigation is Successful 14Jun June, Tuesday 14 2011¬ 09:49 EDT Apricus Biosciences Added to Russell Microcap Index 03Jun June, Friday 03 2011¬ 10:23 EDT Apricus Bio CEO to Present Commercialization Plans for Vitaros^® at Jefferies 2011 Global Healthcare Conference 02Jun June, Thursday 02 2011¬ 12:06 EDT Apricus Biosciences Appoints Steve Martin as Senior Vice President and Chief Financial Officer 01Jun June, Wednesday 01 2011¬ 15:10 EDT Apricus Biosciences Produces Videos Describing the Mechanism by Which Its NexACT^® Technology Successfully Delivers Drugs Through the Skin 31May May, Tuesday 31 2011¬ 9:56 EDT Apricus Biosciences Announces Issuance of Key Patent for RayVa™ for Raynaud's Phenomenon in Israel 26May May, Thursday 26 2011¬ 13:40 EDT Apricus Biosciences' CEO to Present at Jefferies 2011 Global Healthcare Conference 23May May, Monday 23 2011¬ 13:43 EDT Apricus Biosciences to Present at the Euro-Biotech Partnering Forum 2011 to Further Its Partnership Efforts 19May May, Thursday 19 2011¬ 9:50 EDT Apricus Biosciences Will Request Approval of Vitaros^® as a Treatment for Erectile Dysfunction in Switzerland, Based on Guidance From Swiss Regulatory Authorities 18May May, Wednesday 18 2011¬ 11:05 EDT Apricus Biosciences CEO is Interviewed on CDTV.net 10May May, Tuesday 10 2011¬ 13:55 EDT Apricus Biosciences Appoints Randy Berholtz as Executive Vice President, General Counsel and Secretary 10May May, Tuesday 10 2011¬ 9:28 EDT Apricus Biosciences Announces First Quarter 2011 Financial Results Conference Call 03May May, Tuesday 03 2011¬ 10:22 EDT Apricus Biosciences' Corporate Development Executive Interviewed on Steve Crowley's American Scene 28Apr April, Thursday 28 2011 ¬ 10:11 EDT Apricus Biosciences Requests Approval of Vitaros^® as a Treatment for Erectile Dysfunction in Europe 27Apr April, Wednesday 27 2011 ¬ 13:01 EDT Apricus Biosciences to Present at the FSX Investor Conference in San Francisco on April 28, 2011 19Apr April, Tuesday 19 2011 ¬ 10:35 EDT Apricus Biosciences Building Strong Pipeline and Solid Financials, CEO, Dr. Bassam Damaj, Tells CEO/CFO Magazine 13Apr April, Wednesday 13 2011 ¬ 15:40 EDT Apricus Biosciences Files for Orphan Drug Designation for RayVa™ 05Apr April, Tuesday 05 2011 ¬ 12:22 EDT Apricus Biosciences' CEO Interviewed by WallStreetCorner.com 31Mar March, Thursday 31 2011 ¬ 10:46 EDT Apricus Biosciences Expands Patent Coverage in Mexico for Its Erectile Dysfunction Drug, Vitaros^® 24Mar March, Thursday 24 2011 ¬ 9:59 EDT Apricus Biosciences Adopts Shareholder Rights Plan 22Mar March, Tuesday 22 2011 ¬ 9:55 EDT Apricus Biosciences Announces Poster Presentations on Progress of PrevOnco™ in Combination With NexACT^® Technology at the American Association for Cancer Research 2011 Annual Meeting 15Mar March, Tuesday 15 2011 ¬ 10:01 EDT Apricus Biosciences Announces Formation of Clinical Advisory Board as Part of Its Plans to Further the Clinical Development of Femprox^® 10Mar March, Thursday 10 2011 ¬ 9:58 EDT Apricus Biosciences to Present at the Bio-Europe Spring 2011 Conference 09Mar March, Wednesday 09 2011 ¬ 9:31 EDT Apricus Biosciences Announces 2010 Year End Financial Results Conference Call 08Mar March, Tuesday 08 2011 ¬ 9:59 EDT Apricus Biosciences Announces Removal of Auditor's "Going Concern" Opinion From Its 2010 Form 10-K and Increased Cash Reserves 01Mar March, Tuesday 01 2011 ¬ 9:16 EDT Apricus Biosciences Announces Expanded European Patent Coverage for MycoVa™ for Nail Fungus 17Feb February, Thursday 17 2011 ¬ 9:17 EDT Apricus Biosciences and FDA Initiate PrevOnco™ SPA Phase III Clinical Protocol Discussion 14Feb February, Monday 14 2011 ¬ 10:20 EDT Apricus Biosciences and Neopharm Group Sign Licensing Agreement for Vitaros^® in Israel for up to $4.35 Million, Plus Royalties 10Feb February, Thursday 10 2011 ¬ 10:14 EDT Apricus Biosciences to Present Review of Commercialization Plans for Vitaros^® and Development of Product Pipeline at BioPartnering North America Conference(TM) 28jan January, Friday 28 2011 ¬ 11:03 EDT Apricus Biosciences Presents Data on Oral Use of Nexact(R) Technology at the Controlled Release Society Conference 26jan January, Wednesday 26 2011 ¬ 12:03 EDT Apricus Biosciences' Chief Executive Officer is Interviewed on CDTV.net 19jan January, Wednesday 19 2011 ¬ 12:03 EDT Apricus Biosciences Reports Additional Analysis Showing That MycoVa™ is as Effective for the Treatment of Nail Fungus as the Current European Standard of Care for Topical Therapy, Loceryl(R) 14jan January, Friday 14 2011 ¬ 12:03 EDT Apricus Bio Announces Expansion Of Patent Portfolio for Topical Cream to Treat Premature Ejaculation with Issuance Of Japanese Patent 12jan January, Wednesday 12 2011 ¬ 13:51 EDT Management of Apricus Bio Highlights Corporate Development, Drug Registration and Out-Licensing Progress at Two Biotech Conferences 04jan January, Tuesday 04 2011 ¬ 10:13 EDT Apricus Biosciences and Elis Pharma Sign License Agreement for Vitaros^® in the Gulf and Part of the Middle East; Apricus Bio to Receive up to $2.1 Million, Plus Royalties 2010 22dec December, Wednesday 22 2010 ¬ 11:12 EDT Apricus Biosciences and Bracco Sign Licensing Agreement for Vitaros^® in Italy; Apricus Bio to Receive Up to EUR 5.5 Million, Plus Royalties 13dec December, Monday 13 2010 ¬ 14:00 EDT Apricus Biosciences Announces Upcoming Presentations at the 4^th Annual OneMedForum San Francisco and the Biotech Showcase 2011 06dec December, Monday 06 2010 ¬ 14:54 EDT Apricus Biosciences Launches Educational Video Series Focused On Its Newly Approved Erectile Dysfunction Drug, Vitaros^® 01dec December, Wednesday 01 2010 ¬ 15:59 EDT Apricus Biosciences Appoints Manufacturer for Vitaros^® , Its Newly Approved Drug to Treat Erectile Dysfunction in Canada 29nov November, Monday 29 2010 ¬ 15:12 EDT Apricus Biosciences Announces New NexACT^® Transbuccal Delivery Data Published in the International Journal of Pharmaceutics 22nov November, Monday 22 2010 ¬ 15:13 EDT Apricus Biosciences Files Phase 3 Registration Protocol for PrevOnco™ for Special Protocol Assessment Consideration by the FDA 19nov November, Friday 19 2010 ¬ 15:03 EDT Apricus Bio Announces Pre-Clinical Data Showing Significant Improvement in Solubility and Absorption of NexACT^® -Based Small Molecule Drugs Selected from the Biopharmaceutics Classification System 17nov November, Wednesday 17 2010 ¬ 15:00 EDT Apricus Biosciences' CEO Bassam Damaj, Ph.D., Interviewed by the Financial Network CDTV.net 15nov November, Monday 15 2010 ¬ 17:21 EDT Apricus Biosciences Receives Canadian Approval for Vitaros^® as First Line Therapy for Erectile Dysfunction 10nov November, Wednesday 10 2010 ¬ 15:39 EDT Apricus Biosciences Announces 2010 Third Quarter Financial Results Conference Call 09nov November, Tuesday 09 2010 ¬ 17:40 EDT Apricus Bio's VP of Investor Relations, Edward Cox, Interviewed by Steve Crowley's American Scene 05nov November, Friday 05 2010 ¬ 16:35 EDT Apricus Bio Apricus Bio Awarded Three Qualifying Therapeutic Discovery Project Grants 25oct October, Monday 25 2010 ¬ 16:40 EDT Apricus Bio Announces Formation of Clinical Advisory Board 21oct October, Thursday 21 2010 ¬ 13:01 EDT Apricus Biosciences to Present at the FSX Investor Conference in Phoenix, AZ on October 29, 2010 18oct October, Monday 18 2010 ¬ 16:30 EDT Apricus Bio Announces First Patent Grant for Femprox^® In Japan 14oct October, Thursday 14 2010 ¬ 14:00 EDT Apricus Bio Announces IND Filing for Nupen™, Its Proprietary Topical Nupen™ Formulation Containing NexACT^® 13oct October, Wednesday 13 2010 ¬ 14:02 EDT Apricus Bio Provides Update on Development Activities 11oct October, Monday 11 2010 ¬ 13:00 EDT Apricus Biosciences To Present At The Precisionir Informed Investors Forum Biotech, Healthcare And Pharma Virtual Conference On October 13 08oct October, Tuesday 08 2010 ¬ 13:00 EDT Apricus Bio Highlighted in Investment Newsletter 05oct October, Tuesday 05 2010 ¬ 12:00 EDT Apricus Bio Closes Securities Offering, Raising over $9.3 Million 29sep September, Wednesday 29 2010 ¬ 12:30 EDT Apricus Bio Announces Pricing of Securities Offering 21sep September, Tuesday 21 2010 ¬ 19:11 EDT Apricus Bio Receives FDA Guidance on Phase 3 Study Design for RayVa™ Treatment for Raynaud's Syndrome, Secondary to Scleroderma 20sep September, Monday 20 2010 ¬ 15:00 EDT Apricus Bio Announces Confirmatory Results Qualifying NexACT^® as an Anti-Microbial Preservative 14sep September, Tuesday 14 2010 ¬ 13:50 EDT Apricus Biosciences Announces Pre-Clinical Results Showing the Ability of the NexACT^® Technology to Enable Rectal Delivery of Biologics 10sep September, Friday 10 2010 ¬ 20:31 EDT NexMed, Inc. Announces Results of Special Meeting of Stockholders, Including Name Change to Apricus Biosciences 25aug August, Wednesday 25 2010 ¬ 15:00 EDT NexMed To Present at the Rodman & Renshaw 12^th Annual Healthcare Conference 23aug August, Monday 23 2010 ¬ 13:00 EDT NexMed Receives Additional Patent Coverage for Israel 26jul July, Monday 26 2010 ¬ 16:36 EDT Mohamed Hachicha, Ph.D. Joins NexMed, Inc. as Vice President-Research and Development for NexMed, USA 07jul July, Wednesday 07 2010 ¬ 12:30 EDT NexMed Regains Compliance with NASDAQ Listing Requirements 28jun June, Monday 28 2010 ¬ 16:09 EDT NexMed to Present PrevOnco™ Data at ILCA Annual Conference 24jun June, Thursday 24 2010 ¬ 17:20 EDT NexMed Announces First Patent Allowance for Vitaros^® in Japan 23jun June, Wednesday 23 2010 ¬ 17:54 EDT NexMed Receives Screening Acceptance Letter from Health Canada for Vitaros^® 22jun June, Tuesday 22 2010 ¬ 13:15 EDT NexMed Announces Appointment of Deirdre Y. Gillespie, M.D. to the Board of Directors 15jun June, Tuesday 15 2010 ¬ 13:20 EDT NexMed Announces Pre-Clinical Results Showing That Its Proprietary Calcipotriene Betamethasone Psoriasis Formulation is Bioequivalent to Talconex^® 10jun June, Thursday 10 2010 ¬ 9:07 EDT NexMed Provides Update on Canadian Filing for Vitaros^® 25may May, Tuesday 25 2010 ¬ 21:00 EDT NexMed Announces Expansion of Senior Business Development Team 17may May, Monday 17 2010 ¬ 21:11 EDT NexMed to Discuss P2/3 Protocol for NexACT^® -Based Alprostadil Treatment for Raynaud's Syndrome with the FDA 12may May, Wednesday 12 2010 ¬ 15:19 EDT Nexmed Announces Pre-Clinical Study Showing Vitaros^® Significantly Promotes Wound Healing 10may May, Monday 10 2010 ¬ 21:19 EDT NexMed Announces Encouraging Pre-Clinical Results Showing the Ability of the NexACT^® Technology to Enhance the Bioavailability of rituximab When Administered Subcutaneously 06may May, Thursday 6 2010 ¬ 20:45 EDT NexMed Expands Scientific Advisory Board with Appointment of Key Industry Leaders 05may May, Wednesday 5 2010 ¬ 20:36 EDT NexMed Announces Patent Allowance for NexACT^® in Canada 28Apr April, Wednesday 28 2010 ¬ 22:47 EDT Pre-Clinical Results Show NexACT^® Technology Significantly Improves Subcutaneous Delivery and Anti-Metastatic Activity of Angstrom's A6 Cancer Compound 27Apr April, Tuesday 27 2010 ¬ 20:40 EDT NexMed Appoints Dr. Stephen B. Howell, World Renowned Key Opinion Leader in Oncology as Chairman of Its Scientific Advisory Board 26Apr April, Monday 26 2010 ¬ 14:11:23 EDT NexMed Receives FDA Clearance for PrevOnco™ Phase 2 Study as First-Line Therapy for HCC 22Apr April, Friday 22 2010 ¬ 00:50 EDT NexMed Files CMC Response with Health Canada for Vitaros^® 13Apr April, Tuesday 13 2010 ¬ 15:00 EDT NexMed and Ångstrom Pharmaceuticals to Present Data on Å6 Drug at AACR 09Apr April, Friday 09 2010 ¬ 13:00 EDT NexMed Announces Expansion of Its Bio-Quant Subsidiary Facilities 05Apr April, Monday 05 2010 ¬ 13:15 EDT NexMed Announces the Expansion of Its Senior Management Team 29Mar March, Monday 29 2010 ¬ 11:18 EDT Nexmed Files Investigational New Drug Application with Fda for Cancer Drug Candidate 25Mar March, Thursday 25 2010 ¬ 14:00 EDT NexMed, Inc. to Co-Sponsor Biotalk of Dr. Diego Miralles of Johnson & Johnson at the San Diego Biotechnology Discussion Group 23Mar March, Tuesday 23 2010 ¬ 17:21 EDT NexMed, Inc. Enters into Distribution Agreement for Japan 17Mar March, Wednesday 17 2010 ¬ 14:00 EDT NexMed Announces the Ability of Its NexACT^® Technology to Deliver Insulin and Taxol Subcutaneously in a Depot-Like Fashion 17Mar March, Wednesday 17 2010 ¬ 12:30 EDT NexMed Bolsters Its Cash Reserve with $1.4 Million Infusion from Successful Mortgage Refinancing on Its New Jersey Facility 09Mar March, Tuesday 09 2010 ¬ 11:06:15 Nexmed To Present At The Roth 22Nd Annual Oc Growth Stock Conference 08Feb February, Monday 08 2010 ¬ 14:54:29 NexMed Receives over $2.7 Million Cash Infusion 01Feb February, Monday 01 2010 ¬ 14:54:29 NexMed Granted Request for Continued Listing on NASDAQ 19Jan January, Tuesday 19 2010 ¬ 14:54:29 Nexmed Updates on Canadian Aproval Process for Vitaros^® 12Jan January, Tuesday 12 2010 ¬ 14:54:29 NexMed Announces the Ability of the NexACT^® Technology to Deliver Drugs Orally and with Enhanced Bioavailability 08Jan January, Friday 08 2010 ¬ 10:48:29 NexMed Provides Corporate Update

© 2012 Apricus Biosciences, Inc. All Rights Reserved.

Contact Us Terms of Use Agreement Privacy Policy Safe Harbor Subscribe Sitemap